Skip to main contentAI and Advanced
/
SANOFI · NSEBSE SENSEX74,336.45+0.45%BSE |
NIFTY 5023,217.6+0.43%NSE |
NIFTY BANK56,292.45+0.89%NSE |
NIFTY IT29,087.65-1.58%NSE |
NIFTY AUTO26,893.65+0.51%NSE |
NIFTY FMCG45,559+1.63%NSE |
NIFTY PHARMA26,146.2-0.16%NSE |
NIFTY 50022,532+0.24%NSE |
SA
NSE · Equity shares · Biotechnology & Drugs-5.70 · -0.18%
Sanofi India SANOFI
NSE:INR 3,125.3
BSE:INR 3,130
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for SANOFI
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 3,131
Day rangeINR 3,081 — INR 3,149
52-week rangeINR 3,054 — INR 5,551.05
Volume18,139
Market cap7,722.84
P/E24.23
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)1,837.4
Net Income (INR Cr)326.7
Rev Growth (5 Year %)-8.74
EPS Growth (5 Year %)-7.31
P/E Ratio24.23
Book Value358.35
EPS150.15
Price/BV8.72Computed
Research path: Interpret Sanofi India's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
SANOFISanofi India1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2025 | 2024 | 2023 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 1,254.8 | 1,611.8 | 1,714.8 |
| Accumulated Depreciation Total | -265.4 | -241.3 | -218.8 |
| Cash Equivalents | 230.2 | 243.5 | 328.9 |
| Other Liabilities Total | 0.5 | 18 | 30.7 |
| Accrued Expenses | 19.8 | 54 | 92.8 |
| Common Stock Total | 23 | 23 | 23 |
| Other Current Assets Total | 13.4 | 12.3 | 13.9 |
| Prepaid Expenses | 6.6 | 11.5 | 7.1 |
| Total Assets | 1,254.8 | 1,611.8 | 1,714.8 |
| Current Portof LT Debt/Capital Leases | 4.1 | 5.3 | 5.1 |
| Additional Paid-In Capital | 2 | 2 | 2 |
| Cash | 32.7 | 40.3 | 65.6 |
| Total Equity | 749.2 | 860.6 | 1,015.2 |
| Retained Earnings(Accumulated Deficit) | 724.2 | 835.6 | 990.2 |
| Total Common Shares Outstanding | 2.3 | 2.3 | 2.3 |
| Property/Plant/Equipment Total-Gross | 580.4 | 570.6 | 542.1 |
| Tangible Book Valueper Share Common Eq | 325 | 373.11 | 437.55 |
| Total Liabilities | 505.6 | 751.2 | 699.6 |
| Total Debt | 17.8 | 19.3 | 19 |
| Cashand Short Term Investments | 262.9 | 283.8 | 394.5 |
| Total Receivables Net | 197.3 | 314.7 | 167.1 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 |
| Accounts Receivable-Trade Net | 176.7 | 230 | 131.7 |
| Property/Plant/Equipment Total-Net | 315 | 329.3 | 323.3 |
| Total Current Liabilities | 491.4 | 719.2 | 651.3 |
| Total Inventory | 320.4 | 504.5 | 665.4 |
| Accounts Payable | 194 | 406.3 | 291.5 |
| Other Currentliabilities Total | 273.5 | 253.6 | 261.9 |
| Total Long Term Debt | 13.7 | 14 | 13.9 |
| Intangibles Net | 0.7 | 1.3 | 7.5 |
| Other Long Term Assets Total | 13.6 | 13.6 | 10.7 |
| Note Receivable-Long Term | 124.9 | 140.8 | 125.3 |
| Total Current Assets | 800.6 | 1,126.8 | 1,248 |
| Capital Lease Obligations | 13.7 | 14 | 13.9 |
| Deferred Income Tax | Not available | 0 | 3.7 |
Fundamentals
Valuation and ratios
Growth
Debt 5Yr CAGR %-4.66
Margins
Operating Margin 12m23.2
Operating Margin 5y Avg28.15
Net Profit Margin 12m17.94
Net Profit Margin 5y22.21
Yield
Dividend Yield %3.7
Valuation
Price to Sale Ratio4.20
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskModerate risk
Board Risk21.64
Analyst consensus
ConsensusBuy
Consensus score2.00
Analyst opinions3
Strong Sell count0
Sell count0
Hold count1
Buy count1
Strong Buy count1
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 60.40%
- FII
- 5.69%
- MF
- 9.14%
- Other
- 24.77%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Muthoot Finance, Sanofi India to trade ex-dividend today; Ami Organics to trade ex-split todayMarket news · 25 Apr 2025, 9:02 am
Dividend Stocks: Muthoot Finance, Sanofi India share prices will remain in focus on Friday as will trade ex-dividend today. In addition Ami Organics shares will also remain in focus as will trade ex-split today. The record date for dividend and stock split of these companies stands on 25 April 2025
Sanofi India share price rises up to 6% post Q4 results, Dividend announcementsMarket news · 28 Feb 2025, 11:45 am
Stock Market Today: Sanofi India share price gained up to 6% in morning trades on Friday post Q4 results announced by the company after the market hours on Thursday. Sanofi India also announced dividend of ₹ 117 per share of face value of ₹ 10.
Stocks to watch: RVNL, Coal India, LIC, TVS Motor, Tata Power, among key shares to remain in focus today - February 28Market news · 28 Feb 2025, 7:57 am
Stocks to watch: In today’s stock market trade, a slew of stocks will be on investors’ radar, including Tata Power, Life Insurance Corporation of India, RVNL, Sanofi India, PB Fintech, Coal India, TVS Motor Company, InterGlobe Aviation, SpiceJet, among others.
Sanofi, Schaeffler share price in focus as companies to consider dividend todayMarket news · 27 Feb 2025, 9:14 am
Dividend stocks 2025: Sanofi India, Schaeffler India share prices will remain in focus on Thursday as will declare dividend today. The meeting of the board of directors of the companies is scheduled for today to consider un audited financial results and dividend issue.
Glenmark, JB Pharma, Ajanta, Zydus, Sanofi lead Indian Pharma Market growth during May'2024Market news · 14 Jun 2024, 1:21 pm
Stock Market Today: Glenmark Pharmaceuticals , JB Pharma, Ajanta Pharma, Zydus LifeSciences, Sanofi India lead Indian Pharma Market growth during May 2024. IPM grew at a healthy pace of 10% . Check for underperformers, other details and forward prospects.
Stocks to watch: Shriram Finance, Airtel, Vedanta, Sanofi India, DLF, ZomatoMarket news · 14 May 2024, 7:56 am
Here are a few stocks likely to be in focus on Tuesday, May 14:
Corporate actions
Events
- board MeetingsQuarterly Results
- annual General MeetingA.G.M
- board MeetingsQuarterly Results
- dividendRs.48.0000 per share(480%)Final Dividend
- board MeetingsQuarterly Results & Interim Dividend
- annual General MeetingPOM
- dividendRs.75.0000 per share(750%)Interim Dividend
- board MeetingsQuarterly Results & Interim Dividend
Rusaka Markets Community
Discussion and sentiment for Sanofi India
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Sanofi India Limited is an India-based company, which is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. The Company produces pharmaceutical formulations, dosage forms and offer a range of medicines across various therapeutic areas. Its product portfolio is focused on five therapeutic areas: diabetes, epilepsy, cardiology, allergy and pain care. In the diabetes area, the Company has an insulin portfolio under the brand name of Lantus, which helps in controlling high blood sugar in adults and children with diabetes mellitus. It also provides Toustar pen, along with dedicated Toujeo cartridges, addressing the need for a reusable delivery device. Combiflam, its product, helps to reduce pain and inflammation in conditions like headache, muscle and joint pain, and also reduces fever. Its brands also include Cardace, Allegra, Avil and Frisium. The Company has its own manufacturing facility in Goa. It has around 12 contract manufacturing organizations.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- SANOFI
- BSE Code
- 500674
Questions
Stock FAQ
What is the symbol and ISIN of Sanofi India?
Sanofi India has the symbol SANOFI and ISIN - INE058A01010.
What is the current price of Sanofi India?
Sanofi India is currently trading at INR 3,125.30.
What are the year high and year low of Sanofi India?
Sanofi India has a year high of INR 5,551.05 and a year low of INR 3,054.00.
What is the market capitalization of Sanofi India?
Sanofi India has a market capitalization of INR 7,722.84 crore.
What is the P/E ratio of Sanofi India?
Sanofi India has a P/E ratio of 24.23.
What is the dividend yield of Sanofi India?
Sanofi India has a dividend yield of 3.70%.
How is the financial performance of Sanofi India based on revenue, net income, and EPS?
Sanofi India has revenue of INR 1,837.40 crore, net income of INR 326.70 crore, and EPS of INR 149.40.
What is the book value of Sanofi India?
Sanofi India has a book value of INR 358.35.
What is the debt-to-equity ratio of Sanofi India?
Sanofi India has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Sanofi India?
Sanofi India has a price-to-book ratio of 8.72 and a price-to-sales ratio of 4.20.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.